26 Gy分6次的大分割乳房切除术后放疗十年结局
该回顾性研究纳入2000至2009年454例I至III期乳腺癌患者,接受26 Gy分6次、历时5周的大分割乳房切除术后放疗,中位随访10.6年。10年局部区域复发累积发生率为15.1%,心脏疾病发生率3.3%、有症状肺纤维化1.5%、手臂淋巴水肿累积发生率9.5%(其中20例为重度,占4.4%)。作者认为该方案似乎安全,但局部区域复发似乎略高于文献报道,凸显长期随访和随机试验的必要性。
要点
- 454例I至III期乳腺癌患者接受26 Gy分6次、历时5周的大分割乳房切除术后放疗,中位随访10.6年。
- 10年局部区域复发累积发生率为15.1%,区域淋巴结≥4枚受累与更差的局部区域控制(HR 1.68)和总生存(HR 2.16)相关。
- 心脏疾病发生率3.3%、有症状肺纤维化1.5%、手臂淋巴水肿10年累积发生率9.5%(重度20例,4.4%)。
核心结论
- 作者认为26 Gy分6次、历时5周的大分割乳房切除术后放疗似乎安全,但局部区域复发似乎略高于文献报道,凸显长期随访和随机试验的必要性。
研究设计与样本
- 回顾性研究,纳入2000至2009年接受大分割乳房切除术后放疗的I至III期乳腺癌患者454例。
- 放疗方案为4次4 Gy(第1、3、15、17天)后2次5 Gy(第29、31天),历时5周,采用三维适形放疗照射胸壁,必要时包括区域淋巴结区。
- 中位随访10.6年(范围0.5至22.9年),84.1%的患者接受区域淋巴结照射。
主要发现
- 10年局部区域复发累积发生率为15.1%。
- 多因素分析中,区域淋巴结受累≥4枚与更差的局部区域控制相关(HR 1.68;95%CI 1.06至2.67;P=0.03),也与更差的总生存相关(HR 2.16;95%CI 1.59至2.95;P<0.001)。
- 随访期间心脏疾病发生率为3.3%,有症状肺纤维化为1.5%,手臂淋巴水肿10年累积发生率为9.5%,其中20例(4.4%)被认为严重。
关键数值与推荐
- 原文未报告指南或共识推荐条款。
临床怎么用
- 原文未据此给出推荐;作者结论为26 Gy分6次、历时5周的大分割乳房切除术后放疗似乎安全,但局部区域复发似乎略高于文献报道,凸显长期随访和随机试验的必要性。
局限性
- 原文为回顾性研究。
- 原文结论指出局部区域复发似乎略高于文献报道,凸显长期随访和随机试验的必要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the efficacy and long-term side effects of hypofractionated postmastectomy radiation therapy (HFRT-PM) of 26 Gy in 6 fractions over 5 weeks. METHODS AND MATERIALS: We retrospectively reviewed characteristics and outcomes of patients with stage I to III breast cancer treated with HFRT-PM between 2000 and 2009. Treatment provided 4 fractions of 4 Gy (days 1, 3, 15, 17) and then 2 fractions of 5 Gy (days 29 and 31) over 5 weeks. The treatment techniques were applied by using 3-dimensional conformal radiation therapy of the chest wall with regional nodal volume if required. RESULTS: We identified 454 patients with a median follow-up of 10.6 years (range, 0.5-22.9). Regional nodal irradiation was done in 84.1% of patients. At 10 years, the cumulative incidence of locoregional relapse was 15.1%. In multivariate analysis, regional lymph node involvement (≥4 nodes) was associated with worse locoregional control (hazard ratio, 1.68; 95% confidence interval, 1.06-2.67; P = .03) and overall survival (hazard ratio, 2.16; 95% confidence interval, 1.59-2.95; P < .001). The toxicities were acceptable. The incidence of cardiac disorders (3.3%), and symptomatic lung fibrosis (1.5%) was low during follow-up. At 10 years, the cumulative rate of arm lymphedema was 9.5% and considered severe in 20 patients (4.4%). CONCLUSIONS: The long-term results of this study show that HFRT-PM of 26 Gy in 6 fractions over 5 weeks seems safe, but locoregional recurrence seems slightly higher than that observed in the literature, highlighting the need for long-term follow-up and for randomized trials for hypofractionated radiation therapy postmastectomy.
引用
- Mignot F, Quero L, Guillerm S, et al. Ten-Year Outcomes of Hypofractionated Postmastectomy Radiation Therapy of 26 Gy in 6 Fractions. Int J Radiat Oncol Biol Phys. 2021. PMID: 34963557. doi:10.1016/j.ijrobp.2021.12.154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。